Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

1(33%)

Results Posted

100%(1 trials)

Phase Distribution

Ph phase_2

67%

Ph phase_3

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 2Efficacy & side effects

2(66.7%)

Phase 3Large-scale testing

1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(1)

Detailed Status

Active, not recruiting1

Completed1

Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 22 (66.7%)

Phase 31 (33.3%)

Trials by Status

active_not_recruiting133%

completed133%

enrolling_by_invitation133%

Recent Activity

1 active trials

Showing 3 of 3

active_not_recruitingphase_3

Study of Bitopertin in Participants With EPP or XLP (APOLLO)

NCT06910358

completedphase_2

Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP

NCT05308472

enrolling_by_invitationphase_2

HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP

NCT05883748

Clinical Trials (3)

Showing 3 of 3 trials

NCT06910358Phase 3

Study of Bitopertin in Participants With EPP or XLP (APOLLO)

Active Not Recruiting

NCT05308472Phase 2

Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP

Completed

NCT05883748Phase 2

HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP

Enrolling By Invitation

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3